This experiment proved that naïve-T cells can be directly activated by co-culture of MHC+ tumor cells and CD28 co-stimulatory signals, and the tumor-specific T-cells might be largely produced from peripheral blood without the use of virus, in which it completely avoided the shortcomings of viral safety and non-specific activation of current ACT therapy, and might become the most promising tumor-specific T cell therapy. This evidence concerns the gene CD28 and neoplasm.